Regulatory Ray Therapeutics receives EMA PRIME status for gene therapy Pharmaceutical TechnologyRay Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).Gene Therapy PlatformRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Technology Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP). Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Survodutide delivers 16.6% weight loss in major phase 3 obesity trialNext: Regeneron Q1 2026 net income falls 10% to $727m Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
